Authors
Latest:
Dr. Chapman on Targeted Treatments for Non-Traditional Mutations in MelanomaPaul B. Chapman, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, professor of medicine at the Weill Cornell Medical College, discusses targeted treatments for non-traditional mutations in melanoma.
Latest:
Paul Jacobsen Discusses Survivorship Care PlansPaul Jacobsen, from the H. Lee Moffitt Cancer Center and Research Institute, Discusses Survivorship Care Plans
Latest:
Dr. Baas on Next Steps in the Treatment of MesotheliomaPaul Baas, MD, professor, Department of Thoracic Oncology, Netherlands Cancer Institute, discusses the future of treatment in mesothelioma.
Latest:
Dr. Baas on Immunotherapy in Mesothelioma SubpopulationsPaul Baas, MD, PhD, discusses the benefits of immunotherapy in subpopulations of patients with mesothelioma.
Latest:
Dr. Barr on the Implications of the Long-Term Results of the RESONATE-2 Trial in CLLPaul M. Barr, MD, discusses the clinical implications of the long-term results of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.
Latest:
Beresford Discusses Using VeriStrat With ImmunotherapiesPaul Beresford, PhD, Biodesix, discusses utilizing VeriStrat technology to select which patients may benefit from immunotherapies.
Latest:
Dr. Chapman on BRAF/MEK Combination for MelanomaDr. Paul Chapman, from Memorial Sloan-Kettering Cancer Center, on Combining BRAF and MEK Inhibitors for Advanced Melanoma
Latest:
Dr Nathan on the Design of the IMCgp100-202 Trial in Uveal MelanomaPaul D. Nathan, MBBS, PhD, FRCP, discusses the design of the phase 3 IMCgp100-202 trial of tebentafusp-tebn in patients with previously untreated, HLA-A*02:01–positive metastatic uveal melanoma, highlighting the key enrollment criteria of the randomized, open-label study.
Latest:
VCU Explores Novel Combos for Solid TumorsStudies conducted at VCU Massey Cancer Center in Richmond, Virginia, over the past 7 years have developed the therapeutic combination of pemetrexed and sorafenib (Nexavar) from the bench to the bedside, and now into phase II clinical trial evaluation.
Latest:
Dr. Oberstein on Remaining Challenges in Metastatic CRCPaul E. Oberstein, MD, discusses remaining challenges in metastatic colorectal cancer.
Latest:
Dr. Eber Discusses Patient Selection for Cytoreductive Nephrectomy in mRCCPaul Eber, MD, urologist, The Conrad Pearson Clinic, discusses patient selection for cytoreductive nephrectomy in the treatment of metastatic renal cell carcinoma.
Latest:
Dr. Corn on Possibility of Immunotherapy for Patients With Prostate CancerPaul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the possibility of immunotherapy in patients with prostate cancer.
Latest:
Dr Richardson on the Potential Significance of Mezigdomide in Relapsed/Refractory Multiple MyelomaPaul G. Richardson, MD, discusses how the continued development of the novel agent mezigdomide could affect the treatment paradigm for patients who progressed on, and developed resistance to, other available BCMA-directed therapies.
Latest:
Dr. Sugarbaker on Perioperative Chemotherapy in Gastrointestinal CancerPaul H. Sugarbaker, MD, FACS, FRCS, chief of the peritoneal surface malignancy program and director of the Center for Gastrointestinal Malignancies at MedStar Washington Hospital Center, discusses the use of perioperative chemotherapy in the treatment of patients with gastrointestinal (GI) cancer.
Latest:
Dr. Harari on Upright Proton Radiation Therapy in Cancer CarePaul M. Harari, MD, discusses the new upright delivery method of proton radiation therapy in cancer care.
Latest:
Dr. Hesketh on Developing Guidelines and ProtocolsDr. Paul J. Hesketh, from Lahey Clinic Medical Center, on Developing Guidelines and Protocols
Latest:
Dr. Shaughnessy on the Potential of the FELIX Trial to Address Unmet Needs in B-ALLPaul J. Shaughnessy, MD, discusses the potential of the phase 1/2 FELIX trial to address unmet needs in relapsed/refractory B-cell acute lymphoblastic leukemia.
Latest:
Paik Provides Insights Into Tepotinib Treatment in NSCLC Harboring MET Exon 14 Skipping AlterationsDr Paik discusses the VISION trial of tepotinib in NSCLC harboring MET exon 14 skipping alterations and real-world data from the TOGETHER pooled analysis.
Latest:
Dr. Marcom on Liquid Biopsies in Breast CancerPaul Kelly Marcom, MD, discusses the use of liquid biopsies in breast cancer treatment.
Latest:
Dr. Barr on the Implications of the Long-Term Results of the RESONATE-2 Trial in CLLPaul M. Barr, MD, discusses the clinical implications of the long-term results of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.
Latest:
Treatment Options for Patients with Stage III & IV Melanoma: Part II: Experimental treatments for stage III/IV or refractory/recurrent melanomaVarious immunotherapeutic strategies to treat advanced melanoma have been under investigation for more than a decade
Latest:
Dr. Mayor on Neuroendocrine Carcinoma in Gynecologic TumorsPaul Mayor, MD, Gynecologic Oncology Fellow, Roswell Park Cancer Institute, discusses neuroendocrine carcinoma in gynecologic tumors.
Latest:
Dr Nathan on the Significance of Tebentafusp in HLA-A*02:01+ Uveal MelanomaPaul D. Nathan, MBBS, PhD, FRCP, discusses the clinical significance of updated data on tebentafusp in metastatic uveal melanoma.
Latest:
Dr. Nghiem on Challenges With Immunotherapy in Merkel Cell CarcinomaPaul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses challenges with immunotherapy in patients with Merkel cell carcinoma
Latest:
Dr. Eber on Takeaways From the CARMENA Trial in mRCCPaul R. Eber, MD, a urologist at Conrad-Pearson Clinic, discusses takeaways from the CARMENA trial in metastatic renal cell carcinoma (mRCC).
